Cargando…

Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study

Although the safety profiles of mRNA COVID-19 vaccines (mRNA-1273 and BNT162b2) were evaluated in pre-authorization clinical trials, real-world data allow us to better define their benefit/risk ratio in the paediatric population. The current study aimed to evaluate the safety profiles of mRNA COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zinzi, Alessia, Gaio, Mario, Liguori, Valerio, Ruggiero, Rosanna, Tesorone, Marina, Rossi, Francesco, Rafaniello, Concetta, Capuano, Annalisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962857/ https://www.ncbi.nlm.nih.gov/pubmed/36851276 http://dx.doi.org/10.3390/vaccines11020401

Ejemplares similares

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2023)

Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database
por: Gamboa, Lorea, et al.
Publicado: (2023)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Calapai, Fabrizio, et al.
Publicado: (2023)

We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2020)

Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database
por: Sportiello, Liberata, et al.
Publicado: (2023)

Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
por: Newbould, Victoria, et al.
Publicado: (2017)

Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance
por: Ruggiero, Rosanna, et al.
Publicado: (2022)

Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
por: Newbould, Victoria, et al.
Publicado: (2017)

An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance
por: Pinheiro, Luis C., et al.
Publicado: (2017)

PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database
por: di Mauro, Gabriella, et al.
Publicado: (2020)

EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection
por: Postigo, Rodrigo, et al.
Publicado: (2018)

Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007–2018
por: Popiołek, Iwona, et al.
Publicado: (2019)

Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives
por: Sardella, Marco, et al.
Publicado: (2019)

Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports
por: Baan, Esmé J., et al.
Publicado: (2019)

The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions
por: Candore, Gianmario, et al.
Publicado: (2021)

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database
por: Rastogi, Shruti, et al.
Publicado: (2022)

Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance
por: Pop, Gabriela, et al.
Publicado: (2022)

Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database
por: Nikitina, Victoria, et al.
Publicado: (2023)

Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database
por: Scavone, Cristina, et al.
Publicado: (2022)

Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database
por: Tobaiqy, Mansour, et al.
Publicado: (2021)

Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance
por: Maltezou, Helena C., et al.
Publicado: (2023)

Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions
por: Correia Pinheiro, Luis, et al.
Publicado: (2021)

Suspected oncologic adverse reactions associated with interleukin‐23 inhibitors in EudraVigilance: Comparative study and gender distribution
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data
por: Segec, Andrej, et al.
Publicado: (2020)

A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database
por: Morgovan, Claudiu, et al.
Publicado: (2023)

A Pharmacovigilance Study Regarding the Risk of Antibiotic-Associated Clostridioides difficile Infection Based on Reports from the EudraVigilance Database: Analysis of Some of the Most Used Antibiotics in Intensive Care Units
por: Vintila, Bogdan Ioan, et al.
Publicado: (2023)

Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)
por: Chiappini, Stefania, et al.
Publicado: (2022)

Comparison of adverse drug reactions among four COVID‐19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites
por: Abbattista, Maria, et al.
Publicado: (2021)

Safety profile of hydroxychloroquine used off‐label for the treatment of patients with COVID‐19: A descriptive study based on EudraVigilance data
por: Motola, Domenico, et al.
Publicado: (2022)

Reported congenital malformations after exposure to non‐tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance
por: Ghalandari, Nafise, et al.
Publicado: (2022)

Characteristics and completeness of spontaneous reports by reporter's role in Germany: An analysis of the EudraVigilance database using the example of opioid‐associated abuse, dependence, or withdrawal
por: Jobski, Kathrin, et al.
Publicado: (2023)

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database
por: Tobaiqy, Mansour, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
por: Mascolo, Annamaria, et al.
Publicado: (2021)

COVID-19 Vaccines and Atrial Fibrillation: Analysis of the Post-Marketing Pharmacovigilance European Database
por: Ruggiero, Rosanna, et al.
Publicado: (2023)

Quinolones-Induced Musculoskeletal, Neurological, and Psychiatric ADRs: A Pharmacovigilance Study Based on Data From the Italian Spontaneous Reporting System
por: Scavone, Cristina, et al.
Publicado: (2020)

Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study
por: Mascolo, Annamaria, et al.
Publicado: (2022)

Did the COVID-19 Pandemic Affect Contrast Media-Induced Adverse Drug Reaction’s Reporting? A Pharmacovigilance Study in Southern Italy
por: Rossi, Claudia, et al.
Publicado: (2022)

Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
por: Rafaniello, Concetta, et al.
Publicado: (2022)

Multisystem Inflammatory Syndrome in Children Following COVID-19 Vaccination: A Sex-Stratified Analysis of the VAERS Database Using Brighton Collaboration Criteria
por: Liguori, Valerio, et al.
Publicado: (2023)

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
por: Gringeri, Michele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j2vnq9e5aqspm8p0a98hei2m4t